Sorrento Therapeutics Inc
OTC:SRNE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sorrento Therapeutics Inc
OTC:SRNE
|
US |
|
GS Holdings Ltd
SGX:43A
|
SG |
|
SBM Offshore NV
OTC:SBFFF
|
NL |
|
Lumen Technologies Inc
F:CYTH
|
US |
|
A
|
Afi Properties Ltd
TASE:AFPR
|
IL |
|
M
|
Marathon Digital Holdings Inc
XMUN:M44
|
US |
|
JD.com Inc
HKEX:89618
|
CN |
|
Nomura Research Institute Ltd
OTC:NRILY
|
JP |
|
B
|
Banco Hipotecario SA
BCBA:BHIP
|
AR |
|
V
|
Vieworks Co Ltd
KOSDAQ:100120
|
KR |
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for Sorrento Therapeutics Inc.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Sorrento Therapeutics Does
Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 949 full-time employees. The company went IPO on 2007-01-19. The firm is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. The company is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist.
- Headquarters
- United States of America US
- Employees
- 949
- IPO date
- Jan 19, 2007
